Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...

Innate immunity, orchestrated by pattern recognition receptors (PRRs) including TLRs, NLRs, and the cGAS–STING pathway, forms the foundation of host ...

A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in ...

Innate lymphoid cells, which curiously behave like T cells even though they don’t recognize specific antigens, show promise as a potential cancer therapeutic. In the years that followed, other groups ...

Unlike transient innate immune activation, trained immunity is characterized by long-lasting but reversible functional reprogramming of monocytes, macrophages, natural killer (NK) cells, and ...

Dozens of new discoveries reveal that defenses evolved by bacteria and viruses billions of years ago still define our own ...

BOSTON, March 13, 2024 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, ...